• Abiraterone in "High-" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. 

  Hoyle, AP; Ali, A; James, ND; Cook, A; Parker, CC; de Bono, JS; Attard, G; Chowdhury, S; Cross, WR; Dearnaley, DP; Brawley, CD; Gilson, C; Ingleby, F; Gillessen, S; Aebersold, DM; Jones, RJ; Matheson, D; Millman, R; Mason, MD; Ritchie, AWS; Russell, M; Douis, H; Parmar, MKB; Sydes, MR; Clarke, NW; STAMPEDE Investigators

  <h4>Background</h4>Abiraterone acetate received licencing for use in only "high-risk" metastatic hormone-naïve prostate cancer (mHNPC) following the LATITUDE trial findings. However, a "risk"-related effect was not seen ...
• Genetic predisposition to prostate cancer: an update. 

  Ni Raghallaigh, H; Eeles, R (2021-01-24)

  Improvements in DNA sequencing technology and discoveries made by large scale genome-wide association studies have led to enormous insight into the role of genetic variation in prostate cancer risk. High-risk prostate ...
• The Association Between Statin Use and Outcomes in Patients Initiating Androgen Deprivation Therapy. 

  Hamilton, RJ; Ding, K; Crook, JM; O'Callaghan, CJ; Higano, CS; Dearnaley, DP; Horwitz, EM; Goldenberg, SL; Gospodarowicz, MK; Klotz, L (2020-12-31)

  <h4>Background</h4>Studies have conflicting results regarding the association between statin use and biochemical recurrence for prostate cancer (PCa). A limited number of studies examining statins in advanced stages report ...
• Prostate cancer - Advantages and disadvantages of MR-guided RT. 

  Murray, J; Tree, AC

  External beam radiotherapy for prostate cancer is an optimal treatment choice for men with localised prostate cancer and is associated with long term disease control in most patients. Image-guided prostate radiotherapy is ...
• Abiraterone in patients with recurrent epithelial ovarian cancer: principal results of the phase II Cancer of the Ovary Abiraterone (CORAL) trial (CRUK-A16037) 

  Banerjee, S; Tovey, H; Bowen, R; Folkerd, E; Kilburn, L; McLachlan, J; Hall, M; Tunariu, N; Attygalle, A; Lima, JPDSN; Perry, S; Chatfield, P; Hills, M; Kaye, S; Attard, G; Dowsett, M; Bliss, JM (SAGE PUBLICATIONS LTD, 2020-12-01)
• Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP trial. 

  Brand, DH; Brüningk, SC; Wilkins, A; Fernandez, K; Naismith, O; Gao, A; Syndikus, I; Dearnaley, DP; Tree, AC; van As, N; Hall, E; Gulliford, S; CHHiP Trial Management Group (2021-01-04)

  <h4>Purpose</h4>Changes in fraction size of external beam radiotherapy (EBRT) exert non-linear impacts on subsequent toxicity. Commonly described by the linear-quadratic model, fraction size sensitivity of normal tissues ...
• Relationship of self-reported body size and shape with risk for prostate cancer: A UK case-control study. 

  Aladwani, M; Lophatananon, A; Robinson, F; Rahman, A; Ollier, W; Kote-Jarai, Z; Dearnaley, D; Koveela, G; Hussain, N; Rageevakumar, R; Keating, D; Osborne, A; Dadaev, T; Brook, M; British Association of Urological Surgeons’ Section of Oncology; Eeles, R; Eeles, R; Muir, KR (2020-01)

  <h4>Introduction</h4>Previous evidence has suggested a relationship between male self-reported body size and the risk of developing prostate cancer. In this UK-wide case-control study, we have explored the possible association ...
• NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. 

  Hall, WA; Paulson, E; Davis, BJ; Spratt, DE; Morgan, TM; Dearnaley, D; Tree, AC; Efstathiou, JA; Harisinghani, M; Jani, AB; Buyyounouski, MK; Pisansky, TM; Tran, PT; Karnes, RJ; Chen, RC; Cury, FL; Michalski, JM; Rosenthal, SA; Koontz, BF; Wong, AC; Nguyen, PL; Hope, TA; Feng, F; Sandler, HM; Lawton, CAF (2021-01)

  <h4>Purpose</h4>In 2009, the Radiation Therapy Oncology Group (RTOG) genitourinary members published a consensus atlas for contouring prostate pelvic nodal clinical target volumes (CTVs). Data have emerged further informing ...
• Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era'': Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019) 

  James, ND; Spears, MR; Clarke, NW; Dearnaley, DP; De Bono, JS; Gale, J; Hetherington, J; Hoskin, PJ; Jones, RJ; Laing, R; Lester, JF; McLaren, D; Parker, CC; Parmar, MKB; Ritchie, AWS; Russell, JM; Strebel, RT; Thalmann, GN; Mason, MD; Sydes, MR (2015-06)
• Increased Dose to Organs in Urinary Tract Associates With Measures of Genitourinary Toxicity in Pooled Voxel-Based Analysis of 3 Randomized Phase III Trials. 

  Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; Greer, PB; Holloway, LC; Dowling, JA; Jameson, MG; Roach, D; Joseph, DJ; Gulliford, SL; Dearnaley, DP; Sydes, MR; Hall, E; Ebert, MA (2020-01)

  <b>Purpose:</b> Dose information from organ sub-regions has been shown to be more predictive of genitourinary toxicity than whole organ dose volume histogram information. This study aimed to identify anatomically-localized ...
• Reduced Dose Posterior to Prostate Correlates With Increased PSA Progression in Voxel-Based Analysis of 3 Randomized Phase 3 Trials. 

  Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; Greer, PB; Holloway, LC; Dowling, JA; Jameson, MG; Roach, D; Joseph, DJ; Gulliford, SL; Dearnaley, DP; Sydes, MR; Hall, E; Ebert, MA (2020-12)

  <h4>Purpose</h4>Reducing margins during treatment planning to decrease dose to healthy organs surrounding the prostate can risk inadequate treatment of subclinical disease. This study aimed to investigate whether lack of ...
• Relationships between rectal and perirectal doses and rectal bleeding or tenesmus in pooled voxel-based analysis of 3 randomised phase III trials. 

  Marcello, M; Denham, JW; Kennedy, A; Haworth, A; Steigler, A; Greer, PB; Holloway, LC; Dowling, JA; Jameson, MG; Roach, D; Joseph, DJ; Gulliford, SL; Dearnaley, DP; Sydes, MR; Hall, E; Ebert, MA (2020-09)

  <h4>Background and purpose</h4>This study aimed to identify anatomically-localised regions where planned radiotherapy dose is associated with gastrointestinal toxicities in healthy tissues throughout the pelvic ...
• Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution. 

  Fisher, R; Horswell, S; Rowan, A; Salm, MP; de Bruin, EC; Gulati, S; McGranahan, N; Stares, M; Gerlinger, M; Varela, I; Crockford, A; Favero, F; Quidville, V; André, F; Navas, C; Grönroos, E; Nicol, D; Hazell, S; Hrouda, D; O'Brien, T; Matthews, N; Phillimore, B; Begum, S; Rabinowitz, A; Biggs, J; Bates, PA; McDonald, NQ; Stamp, G; Spencer-Dene, B; Hsieh, JJ; Xu, J; Pickering, L; Gore, M; Larkin, J; Swanton, C (2014-08-27)

  <h4>Background</h4>Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution.<h4>Results</h4>We perform whole exome sequencing ...
• Intrinsic susceptibility MRI identifies tumors with ALKF1174L mutation in genetically-engineered murine models of high-risk neuroblastoma. 

  Jamin, Y; Glass, L; Hallsworth, A; George, R; Koh, D-M; Pearson, ADJ; Chesler, L; Robinson, SP (2014-01)

  The early identification of children presenting ALK(F1174L)-mutated neuroblastoma, which are associated with resistance to the promising ALK inhibitor crizotinib and a marked poorer prognosis, has become a clinical priority. ...
• Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. 

  Dearnaley, DP; Jovic, G; Syndikus, I; Khoo, V; Cowan, RA; Graham, JD; Aird, EG; Bottomley, D; Huddart, RA; Jose, CC; Matthews, JHL; Millar, JL; Murphy, C; Russell, JM; Scrase, CD; Parmar, MKB; Sydes, MR (2014-04)

  <h4>Background</h4>The aim of this trial was to compare dose-escalated conformal radiotherapy with control-dose conformal radiotherapy in patients with localised prostate cancer. Preliminary findings reported after 5 years ...
• A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. 

  Glasspool, RM; Brown, R; Gore, ME; Rustin, GJS; McNeish, IA; Wilson, RH; Pledge, S; Paul, J; Mackean, M; Hall, GD; Gabra, H; Halford, SER; Walker, J; Appleton, K; Ullah, R; Kaye, S; Scottish Gynaecological Trials Group (2014-04)

  <h4>Background</h4>Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in ovarian cancer is the acquisition of DNA methylation. We therefore tested the ...
• Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. 

  Bancroft, EK; Page, EC; Castro, E; Lilja, H; Vickers, A; Sjoberg, D; Assel, M; Foster, CS; Mitchell, G; Drew, K; Mæhle, L; Axcrona, K; Evans, DG; Bulman, B; Eccles, D; McBride, D; van Asperen, C; Vasen, H; Kiemeney, LA; Ringelberg, J; Cybulski, C; Wokolorczyk, D; Selkirk, C; Hulick, PJ; Bojesen, A; Skytte, A-B; Lam, J; Taylor, L; Oldenburg, R; Cremers, R; Verhaegh, G; van Zelst-Stams, WA; Oosterwijk, JC; Blanco, I; Salinas, M; Cook, J; Rosario, DJ; Buys, S; Conner, T; Ausems, MG; Ong, K-R; Hoffman, J; Domchek, S; Powers, J; Teixeira, MR; Maia, S; Foulkes, WD; Taherian, N; Ruijs, M; Helderman-van den Enden, AT; Izatt, L; Davidson, R; Adank, MA; Walker, L; Schmutzler, R; Tucker, K; Kirk, J; Hodgson, S; Harris, M; Douglas, F; Lindeman, GJ; Zgajnar, J; Tischkowitz, M; Clowes, VE; Susman, R; Ramón y Cajal, T; Patcher, N; Gadea, N; Spigelman, A; van Os, T; Liljegren, A; Side, L; Brewer, C; Brady, AF; Donaldson, A; Stefansdottir, V; Friedman, E; Chen-Shtoyerman, R; Amor, DJ; Copakova, L; Barwell, J; Giri, VN; Murthy, V; Nicolai, N; Teo, S-H; Greenhalgh, L; Strom, S; Henderson, A; McGrath, J; Gallagher, D; Aaronson, N; Ardern-Jones, A; Bangma, C; Dearnaley, D; Costello, P; Eyfjord, J; Rothwell, J; Falconer, A; Gronberg, H; Hamdy, FC; Johannsson, O; Khoo, V; Kote-Jarai, Z; Lubinski, J; Axcrona, U; Melia, J; McKinley, J; Mitra, AV; Moynihan, C; Rennert, G; Suri, M; Wilson, P; Killick, E; IMPACT Collaborators; Moss, S; Eeles, RA (2014-09)

  <h4>Background</h4>Men with germline breast cancer 1, early onset (BRCA1) or breast cancer 2, early onset (BRCA2) gene mutations have a higher risk of developing prostate cancer (PCa) than noncarriers. IMPACT (Identification ...
• Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. 

  Lorente, D; Omlin, A; Ferraldeschi, R; Pezaro, C; Perez, R; Mateo, J; Altavilla, A; Zafeirou, Z; Tunariu, N; Parker, C; Dearnaley, D; Gillessen, S; de Bono, J; Attard, G (2014-12)

  <h4>Background</h4>Abiraterone is a CYP17A1 inhibitor that improves survival in castration-resistant prostate cancer (CRPC). Abiraterone is licensed in combination with prednisone 5 mg twice daily to prevent a syndrome of ...
• Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. 

  Rafii, S; Roda, D; Geuna, E; Jimenez, B; Rihawi, K; Capelan, M; Yap, TA; Molife, LR; Kaye, SB; de Bono, JS; Banerji, U (2015-04)

  <h4>Purpose</h4>Novel antitumor therapies against the PI3K-AKT-mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these ...
• Linkage of the CHHiP randomised controlled trial with primary care data: a study investigating ways of supplementing cancer trials and improving evidence-based practice. 

  Lemanska, A; Byford, RC; Cruickshank, C; Dearnaley, DP; Ferreira, F; Griffin, C; Hall, E; Hinton, W; de Lusignan, S; Sherlock, J; Faithfull, S (2020-07-25)

  <h4>Background</h4>Randomised controlled trials (RCTs) are the gold standard for evidence-based practice. However, RCTs can have limitations. For example, translation of findings into practice can be limited by design ...

View more